Publication & Citation Trends
Publications
5 total
764 A phase 1, first-in-human (FIH), open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with advanced solid tumors PDF
Cited by 4
OpenAlex
A phase 1 multiple-ascending dose study to evaluate the safety and tolerability of XmAb23104 (PD-1 x ICOS) in subjects with selected advanced solid tumors (DUET-3).
Cited by 11
OpenAlex
Research Topics
CAR-T cell therapy research
(3)
Cancer Immunotherapy and Biomarkers
(2)
Biosimilars and Bioanalytical Methods
(2)
Immune Response and Inflammation
(1)
Immunotherapy and Immune Responses
(1)
Affiliations
Scripps Research Institute
Xencor (United States)